PROCEPT BioRobotics 과거 순이익 실적
과거 기준 점검 0/6
PROCEPT BioRobotics 의 수입은 연평균 -10.2%의 비율로 감소해 온 반면, Medical Equipment 산업은 연평균 10.4%의 비율로 증가했습니다. 매출은 연평균 46.5%의 비율로 증가해 왔습니다.
핵심 정보
-10.19%
순이익 성장률
42.26%
주당순이익(EPS) 성장률
| Medical Equipment 산업 성장률 | 8.90% |
| 매출 성장률 | 46.50% |
| 자기자본이익률 | -29.47% |
| 순이익률 | -31.82% |
| 최근 순이익 업데이트 | 31 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
PRCT: Execution Reset After Q4 Miss Will Likely Drive Bearish Repricing
Analyst price targets for PROCEPT BioRobotics have reset meaningfully lower, with the fair value estimate moving from about $38.00 to roughly $20.80. Analysts are factoring in recent Q4 misses, reduced 2026 guidance, concerns around Aquablation adoption in a highly competitive benign prostatic hyperplasia market, and questions about the timing and impact of the company's reorganization and pricing changes.
PRCT: Reset Guidance And New BPH Endorsements Will Support Long Term Rebound
The analyst price target for PROCEPT BioRobotics has been revised slightly lower, from about $32.50 to roughly $30.44, as analysts factor in recent Q4 results, reduced 2026 guidance, and concerns about slower Aquablation adoption in a highly competitive benign prostatic hyperplasia market. Analyst Commentary Street research around PROCEPT BioRobotics has shifted toward more cautious positioning, with a cluster of lower price targets and a mix of neutral and negative ratings following Q4 results and updated 2026 guidance.
PRCT: Commercial Reorganization And HYDROS Rollout Will Support Long Term Rebound Potential
Analysts have cut their average price targets on PROCEPT BioRobotics toward the $30 range, with the fair value estimate moving from about $62 to roughly $46.67 as they factor in recent Q4 shortfalls, reduced 2026 guidance, and concerns about slower Aquablation adoption in a competitive benign prostatic hyperplasia market. Analyst Commentary Recent research updates paint a mixed picture, with most firms trimming price targets after Q4 results and reduced 2026 guidance.PRCT: Long Term Margin Targets And Guidance Reset Will Support Rebound
The analyst price target for PROCEPT BioRobotics has been revised from about $50.73 to $32.50 as analysts factor in recent Q4 misses, reduced 2026 guidance, questions around market penetration for Aquablation, and concerns about execution on sales and discounting changes in a competitive BPH market. Analyst Commentary Street research around PROCEPT BioRobotics has shifted toward a more cautious stance, with several firms cutting price targets and reassessing expectations after Q4 results and lower 2026 guidance.PRCT: Higher Modeled Margins And Investor Day Focus Will Support Rebound Potential
Analysts kept their average price target for PROCEPT BioRobotics steady at $62.00, citing updated assumptions that reflect slightly higher modeled revenue growth and profit margin, as well as a lower future P/E multiple. What's in the News PROCEPT BioRobotics scheduled an Analyst/Investor Day titled "PROCEPT BioRobotics Corporation: Analyst/Investor Day," providing the market with a dedicated forum to hear management's latest updates and focus areas (Key Developments).PRCT: Analyst Day And Margin Outlook Will Support Future Stock Rebound
Analysts have modestly adjusted their fair value outlook for PROCEPT BioRobotics, with the updated price target now framed around $50.73 as they refine assumptions on the discount rate, a profit margin of about 13.57%, and a forward P/E of roughly 46.37x. What's in the News PROCEPT BioRobotics scheduled an Analyst/Investor Day event, described as "PROCEPT BioRobotics Corporation Analyst/Investor Day," signaling a focused update for the professional investment community on the business and outlook (Key Developments).PRCT: Inline Revenue Guidance And Conservative Outlook Will Support Rebound Potential
Narrative Update Analysts have cut their fair value estimate for PROCEPT BioRobotics from US$85.00 to US$62.00, citing more conservative views on revenue growth, profit margins, and a much higher assumed future P/E. However, some still see recent stock moves as a stronger reaction than these adjustments alone would suggest.PRCT: Earnings Volatility Setup Will Likely Drive Future Share Repricing
Analysts have reset their price target framework for PROCEPT BioRobotics, with the fair value estimate moving from about $51 to $38 as they factor in lower published targets around $50, modest tweaks to growth and margin assumptions, and a lower future P/E multiple. They still cite what they see as conservative company guidance and potential for outsized stock reactions around quarterly results.PRCT: Stock Reaction Will Recover As Conservative Guidance Sets Up Future Rebound
Analysts have nudged their average price target on PROCEPT BioRobotics slightly higher to about $50.73 from roughly $49.90, citing still healthy growth expectations, a modestly richer future earnings multiple, and the view that recent stock volatility and cautious guidance have led to an overly conservative market reaction. Analyst Commentary Recent Street research reflects a recalibration of expectations rather than a fundamental shift in conviction, with ownership sentiment remaining generally constructive even as price targets move lower.PRCT: Stock Reaction Will Recover As Conservative Guidance And Pullback Normalize
Analysts have modestly reduced their price target on PROCEPT BioRobotics from about $52 to roughly $50 per share, reflecting slightly lower profit margin expectations even as they argue the recent share price reaction to conservative guidance and sector-wide volatility appears overdone. Analyst Commentary Bullish analysts emphasize that the recalibrated $50 price target still implies meaningful upside from current levels, as they view the recent pullback as disconnected from the company’s underlying growth trajectory and operational execution.PRCT: Stock Reaction Will Recover As Guidance Proves Conservative
Analysts have lowered their price target for PROCEPT BioRobotics from $55.60 to $52.10 per share, citing a mix of cautious company guidance and continued anticipation of healthy revenue growth, even with recent market volatility. Analyst Commentary Recent analyst reports reflect a mix of optimistic outlooks and measured caution for PROCEPT BioRobotics, as price targets have been adjusted downward in the context of ongoing market volatility and evolving company guidance.PRCT: Stock Reaction Will Normalize As Sector Volatility Subsides
The analyst consensus fair value target for PROCEPT BioRobotics has been reduced by approximately $5 to $55.60. Analysts attribute the adjustment to updated sales guidance and expectations of continued volatility in the medtech sector.PRCT: Share Price Will Likely React Sharply To Upcoming Earnings Data
Analysts have lowered their price target for PROCEPT BioRobotics from $62.70 to $60.90, citing broad MedTech market volatility and anticipated stock fluctuations. This comes despite expectations of healthy Q3 financial performance.Clinical Adoption And Global Expansion Will Redefine Healthcare
Analysts have updated their price target for PROCEPT BioRobotics, lowering it from $64 to $50 per share. They cite expectations for healthy revenue, but also note increased market volatility and cautious investor sentiment in the MedTech sector.Is PROCEPT BioRobotics (NASDAQ:PRCT) A Risky Investment?
Sep 26
Procept BioRobotics: Increasing Average Selling Price, Initiate At Buy
Aug 14What You Can Learn From PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S After Its 34% Share Price Crash
Aug 09Clinical Adoption And Global Expansion Will Redefine Healthcare
The modest reduction in PROCEPT BioRobotics’ consensus price target to $65.75 reflects a slight downward revision in the company’s future P/E multiple, while profitability remains stable. What's in the News Raised full-year 2025 revenue guidance to $325.5 million, representing 45% year-over-year growth; projected net loss for 2025 is $83.5 million.PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$65.75 Price Target
Aug 08US$77.00: That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After Its Latest Results
Apr 27Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects
Apr 18
HYDROS Robotic System Launch And Aquablation Trials Will Drive Future Market Expansion
Launch of HYDROS Robotic System and FDA approvals likely to increase procedural adoption and drive revenue growth.Procept BioRobotics: Strong Growth, But Profitability Seems Far Away
Mar 11PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$93.86 Price Target
Feb 28What You Can Learn From PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S
Dec 05Procept BioRobotics: Continued Growth Runway Ahead
Nov 26Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102
Oct 31Procept BioRobotics: New Hydros Aquablation System To Fuel Next Leg Of Growth
Sep 12Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval
Aug 27Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%
Aug 25Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results
Aug 04PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce
May 21The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)
Apr 05US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results
Mar 01Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt
Feb 07Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher
Dec 14매출 및 비용 세부 내역
매출 및 비용 세부 내역
PROCEPT BioRobotics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 322 | -102 | 239 | 76 |
| 31 Dec 25 | 308 | -96 | 229 | 71 |
| 30 Sep 25 | 300 | -85 | 219 | 67 |
| 30 Jun 25 | 275 | -84 | 203 | 66 |
| 31 Mar 25 | 249 | -90 | 187 | 66 |
| 31 Dec 24 | 224 | -91 | 171 | 62 |
| 30 Sep 24 | 200 | -100 | 159 | 62 |
| 30 Jun 24 | 177 | -104 | 150 | 57 |
| 31 Mar 24 | 156 | -103 | 141 | 51 |
| 31 Dec 23 | 136 | -106 | 132 | 48 |
| 30 Sep 23 | 116 | -107 | 121 | 44 |
| 30 Jun 23 | 102 | -105 | 113 | 40 |
| 31 Mar 23 | 85 | -98 | 101 | 35 |
| 31 Dec 22 | 75 | -87 | 89 | 29 |
| 30 Sep 22 | 61 | -77 | 79 | 24 |
| 30 Jun 22 | 50 | -69 | 66 | 22 |
| 31 Mar 22 | 41 | -64 | 59 | 19 |
| 31 Dec 21 | 34 | -60 | 51 | 19 |
| 30 Sep 21 | 28 | -57 | 44 | 18 |
| 30 Jun 21 | 21 | -55 | 39 | 17 |
| 31 Mar 21 | 14 | -53 | 34 | 17 |
| 31 Dec 20 | 8 | -53 | 30 | 16 |
| 31 Dec 19 | 6 | -42 | 29 | 13 |
양질의 수익: PRCT 은(는) 현재 수익성이 없습니다.
이익 마진 증가: PRCT는 현재 수익성이 없습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: PRCT은 수익성이 없으며 지난 5년 동안 손실이 연평균 10.2% 증가했습니다.
성장 가속화: 현재 수익성이 없어 지난 1년간 PRCT의 수익 성장률을 5년 평균과 비교할 수 없습니다.
수익 대 산업: PRCT은 수익성이 없어 지난 해 수익 성장률을 Medical Equipment 업계(13.2%)와 비교하기 어렵습니다.
자기자본이익률
높은 ROE: PRCT는 현재 수익성이 없으므로 자본 수익률이 음수(-29.47%)입니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/01 12:46 |
| 종가 | 2026/05/01 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
PROCEPT BioRobotics Corporation는 22명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Rescott | Baird |
| Stephanie Piazzola | BofA Global Research |
| Stephanie Elghazi | BofA Global Research |